Advertisement

Annals of Hematology

, Volume 97, Issue 1, pp 149–159 | Cite as

ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population

  • Ling Huang
  • Fen Zhang
  • Jialong Zeng
  • Hanguo Guo
  • Sichu Liu
  • Xiaojuan Wei
  • Feili Chen
  • Xinmiao Jiang
  • Zhanli Liang
  • Yanhui LiuEmail author
  • Wenyu LiEmail author
Original Article
  • 248 Downloads

Abstract

The prognostic value of anaplastic lymphoma kinase (ALK) expression in patients with anaplastic large-cell lymphoma (ALCL) remains controversial. Data on the clinical features of ALCL in a Chinese population are limited. We retrospectively reviewed 1293 patients with pathologically diagnosed lymphoma at Guangdong General Hospital from June 2007 through August 2016. We evaluated the incidence of ALCL, clinical characteristics, survival status, and outcome of crizotinib use in four relapsed/refractory ALK-positive patients. Among the 1293 patients, 1193 (92.3%) were non-Hodgkin’s lymphoma, and 53 (4.4%) of whom were ALCL. Of the 50 ALCL patients, with a median age of 34 years, were evaluated. Among them, 33 (66.0%) were ALK-positive and 17 (34.0%) were ALK-negative. Significantly, more patients younger than 40 years old were ALK-positive than ALK-negative (66.7 vs. 23.5%; P = 0.003). The 5-year progression-free survival (PFS) for ALK-positive and ALK-negative patients were 61 and 11%, and the 5-year overall survival (OS) were 70 and 22%, respectively. Median PFS and OS were significantly better for patients with ALK-positive than ALK-negative (60.1 vs. 9.4 months, P = 0. 017; not reached vs. 32.7 months, P = 0.021). Multivariate analyses identified ALK expression, stage, and bone marrow involvement as independent prognostic factors for PFS and OS. Four relapsed ALK-positive patients were treated with crizotinib and two died. Our results suggest that ALK expression has different prognostic significance in patients with ALCL. Mechanisms underlying early relapse after chemotherapy and resistance to crizotinib need further investigation.

Keywords

Anaplastic lymphoma kinase (ALK) Anaplastic large-cell lymphoma (ALCL) Prognostic value Crizotinib 

Notes

Funding

This work was supported by Guangdong Provincial Department of Science and Technology Fund Project (to Wenyu Li, Grant No. 2013B021800204 and Grant No.2016A050502028).

Compliance with ethical standards

Informed consent

Informed consent was obtained from all patients for being included in the study.

Competing interests

The authors declare that they have no conflict of interest.

References

  1. 1.
    No authors listed (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89(11):3909–3918Google Scholar
  2. 2.
    Laurent C, Baron M, Amara N et al (2017) Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network. J Clin Oncol 35:2008–2017CrossRefPubMedGoogle Scholar
  3. 3.
    Swerdlow SH, Campo E, Harris NL et al. (2008) World Health Organization classification of tumours of hematopoietic and lymphoid tissues. International Agency for Research on Cancer 4th EditionGoogle Scholar
  4. 4.
    Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tilly H, Gaulard P, Lepage E et al (1997) Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 90:3727–3734PubMedGoogle Scholar
  6. 6.
    Schmitz N, Trümper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418–3425CrossRefPubMedGoogle Scholar
  7. 7.
    Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566CrossRefPubMedGoogle Scholar
  8. 8.
    Lamant L, Dastugue N, Pulford K et al (1999) A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93:3088–3095PubMedGoogle Scholar
  9. 9.
    Hernandez L, Pinyol M, Hernandez S et al (1999) TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94:3265–3268PubMedGoogle Scholar
  10. 10.
    Touriol C, Greenland C, Lamant L et al (2000) Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95:3204–3207PubMedGoogle Scholar
  11. 11.
    Colleoni GW, Bridge JA, Garicochea B et al (2000) ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 156:781–789CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Matsuyama H, Suzuki HI, Nishimori H et al (2011) miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17- producing immunophenotype to anaplastic large cell lymphoma. Blood 118:6881–6892CrossRefPubMedGoogle Scholar
  13. 13.
    Savage KJ, Harris NL, Vose JM et al (2008) ALK-anaplastic largecell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496–5504CrossRefPubMedGoogle Scholar
  14. 14.
    Falini B, Pileri S, Zinzani PL et al (1999) ALK+ lymphoma: clinicopathological findings and outcome. Blood 93:2697–2706PubMedGoogle Scholar
  15. 15.
    Feldman AL, Dogan A, Smith DI et al (2011) Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 117(3):915–919CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vasmatzis G, Johnson SH, Knudson RA et al (2012) Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 120(11):2280–2289CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Parilla Castellar ER, Jaffe ES, Said JW et al (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124(9):1473–1480CrossRefGoogle Scholar
  18. 18.
    Gascoyne RD, Aoun P, Wu D et al (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921PubMedGoogle Scholar
  19. 19.
    Wang YF, Yang YL, Gao ZF et al (2012) Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients. J Hematol Oncol 5:38CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Suzuki R, Kagami Y, Takeuchi K et al (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993–3000PubMedGoogle Scholar
  21. 21.
    Sibon D, Fournier M, Briere J et al (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes del’Adulte trials. J Clin Oncol 30(32):3939–3946CrossRefPubMedGoogle Scholar
  22. 22.
    Park SJ, Kim S, Lee DH et al (2008) Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years’ experience at Asan Medical Center. Yonsei Med J 49:601–609CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kewalramani T, Zelenetz AD, Teruya-Feldstein J et al (2006) Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134:202–207CrossRefPubMedGoogle Scholar
  24. 24.
    Rodriguez J, Munsell M, Yazji S et al (2001) Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19:3766–3770CrossRefPubMedGoogle Scholar
  25. 25.
    Mak V, Hamm J, Chhanabhai M et al (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 31:1970–1976CrossRefPubMedGoogle Scholar
  26. 26.
    Morel A, Brie’re J, Lamant L et al (2017) Long-term outcomes of adults with first-relapsed/ refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: a LYSA/SFGM-TC study. Eur J Cancer 83:146–153CrossRefPubMedGoogle Scholar
  27. 27.
    Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190–2196CrossRefPubMedGoogle Scholar
  28. 28.
    Li R, Morris SW (2008) Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28:372–412CrossRefPubMedGoogle Scholar
  29. 29.
    Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364:775–776CrossRefPubMedGoogle Scholar
  30. 30.
    Gambacorti Passerini C, Farina F, Stasia A et al (2014) Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst 106:djt378CrossRefPubMedGoogle Scholar
  31. 31.
    Mosse YP, Lim MS, Voss SD et al (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 14:472–480CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Armitage JO (2005) Staging non-Hodgkin lymphoma. CA Cancer J Clin 55:368–376CrossRefPubMedGoogle Scholar
  33. 33.
    Seidemann K, Tiemann M, Schrappe M et al (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 97(12):3699–3706CrossRefPubMedGoogle Scholar
  34. 34.
    Chou WC, IJ S, Tien HF et al (1996) Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: special emphasis on the tumor response to 13-cis retinoic acid. Cancer 78(8):1805–1812CrossRefPubMedGoogle Scholar
  35. 35.
    Pittaluga S, Bijnens L, Teodorovic I et al (1996) Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European–American Classification of Lymphoid Neoplasm: a comparison with the Working Formulation. Blood 87:4358–4367PubMedGoogle Scholar
  36. 36.
    Melnyk A, Rodriguez A, Pugh WC et al (1997) Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 89(12):4514–4520PubMedGoogle Scholar
  37. 37.
    Gisselbrecht C, Gaulard P, Lepage E et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Blood 92(1):76–82PubMedGoogle Scholar
  38. 38.
    Lee SS, Cho KJ, Kim CW et al (1999) Clinicopathological analysis of 501 non-Hodgkin’s lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms. Histopathology 35(4):345–354CrossRefPubMedGoogle Scholar
  39. 39.
    Naresh KN, Srinivas V, Soman CS et al (2000) Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO classifications. Ann Oncol 11(Suppl 1):63–67CrossRefPubMedGoogle Scholar
  40. 40.
    [No authors listed] (2000) The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50(9):696–702CrossRefGoogle Scholar
  41. 41.
    Krivolapov IA (2004) The results of histological and immunohistological studies of primary biopsies in 400 patients with non-Hodgkin’s lymphoma in the North-West region of Russia (according to WHO classification). Ter Ark 76(7):64–70Google Scholar
  42. 42.
    Yoon SO, Suh C, Lee DH et al (2010) Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 85(10):760–764CrossRefPubMedGoogle Scholar
  43. 43.
    Chen WL, Tsai WC, Chao TY et al (2010) The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann Hematol 89(6):553–562CrossRefPubMedGoogle Scholar
  44. 44.
    Yang QP, Zhang WY, JB Y et al (2011) Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol 6:77CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sharma M, Mannan R, Madhukar M et al (2014) Immunohistochemical (IHC) analysis of non-Hodgkin’s lymphoma (NHL) spectrum according to WHO/REAL classification: a single centre experience from Punjab, India. J Clin Diagn Res 8(1):46–49PubMedPubMedCentralGoogle Scholar
  46. 46.
    ten Berge RL, de Bruin PC, Oudejans JJ et al (2003) ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43(5):462–469CrossRefPubMedGoogle Scholar
  47. 47.
    Arrowsmith ER, Macon WR, Kinney MC et al (2003) Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma 44(2):241–249CrossRefPubMedGoogle Scholar
  48. 48.
    Gao J, Yin M, Zhu Y et al (2013) Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. BMC Cancer 13:471CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Lakshmaiah KC, Guruprasad B, Shah A et al (2013) Anaplastic large cell lymphoma: a single institution experience from India. J Cancer Res Ther 9(4):649–652CrossRefPubMedGoogle Scholar
  50. 50.
    Han JY, Suh JK, Lee SW et al (2014) Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience. Blood Res 49:246–252CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Turner SD, Lamant L, Kenner L et al (2016) Anaplastic large cell lymphoma in paediatric and young adult patients. Br J Haematol 173:560–572CrossRefPubMedGoogle Scholar
  52. 52.
    Hapgood G, Savage KJ et al (2015) The biology and management of systemic anaplastic large cell lymphoma. Blood 126(1):17–25CrossRefPubMedGoogle Scholar
  53. 53.
    Smith SM, Burns LJ, van Besien K et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31(25):3100–3109CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Ruf R, Brugieres L, Pillon M et al (2015) Risk-adapted therapy for patients with relapsed or refractory ALCL—final report of the prospective ALCL-relapse trial of the EICNHL. Br J Haematol 171:28Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Lymphoma Division, Cancer Center of Guangdong General HospitalGuangdong Academy of Medical SciencesGuangzhouChina
  2. 2.Pathology Department, Guangdong General HospitalGuangdong Academy of Medical SciencesGuangzhouChina
  3. 3.Shantou University Medical CollegeShantouChina

Personalised recommendations